CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 24, 2007
Result type: Reports
Project Number: SR0097-000
Product Line: Reimbursement Review

Generic Name: Posaconazole

Brand Name: Spriafil

Manufacturer: Schering-Plough Canada Inc.

Therapeutic Area: Aspergillus and Candida infections

Indications: Aspergillus and Candida infections

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 30, 2008

Recommendation Type: Do not list